Nippon Kayaku Co., Ltd.
IR Information: Notice Regarding Revision of Earnings Guidance
Revision of consolidated earnings forecasts for the second quarter cumulative period and the full year for the fiscal year ending March 2027. Net sales are expected at 133,800 million yen for the second quarter cumulative period, up 10,300 million yen (YoY +8.3%); operating income 13,700 million yen; ordinary income 13,800 million yen; and quarterly net income attributable to owners of parent per share of 89.35 yen. For the full year, net sales are expected at 270,900 million yen; operating income 27,300 million yen; ordinary income 27,000 million yen; net income attributable to owners of parent 22,900 million yen; and per-share net income 158.66 yen. The revisions reflect strong performance in the Safety Systems, Functional Materials, and Pharmaceuticals segments, along with a weaker yen.
Key Figures
- Net sales (2Q cumulative) 133,800 million yen
- Operating income (2Q cumulative) 13,700 million yen
- Net income attributable to owners of parent (2Q cumulative) 13,100 million yen
AI要約
Revision of Earnings Guidance
Nihon Kagaku has upwardly revised its consolidated earnings forecast for the second quarter cumulative period and the full year for the fiscal year ending March 2027. Sales are robust in the Safety Systems, Functional Materials, and Pharmaceuticals segments, aided by the depreciation of the yen. For the second quarter cumulative period, net sales are expected to be 133,800 million yen, operating income 13,700 million yen, ordinary income 13,800 million yen, net income attributable to owners of parent 13,100 million yen, and net income per share 89.35 yen. For the full year, net sales are expected to be 270,900 million yen, operating income 27,300 million yen, ordinary income 27,000 million yen, net income attributable to owners of parent 22,900 million yen, and net income per share 158.66 yen.
Reasons and Outlook
The revision for this term reflects strong sales performance in the second quarter cumulative period and the impact of the yen’s depreciation. Overall, it is expected to exceed the previous forecast, though future market conditions could cause variability. The contributions from each segment are noted in the body text, and ongoing performance trends warrant close watch.
日本化薬株式会社
Company overview · Stock price · Financial data · All IR
